Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has given written informed consent before any trial-related activity is performed.~* Has a confirmed prostate cancer in which this type of treatment is needed.~Exclusion Criteria:~* Previous treatment for prostate cancer~* Previous trans-urethral resection of the prostate~* Patients who are lymph node positive or have other metastatic disease~* Use of urethral catheter~* Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist.~* History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.~* Hypersensitivity towards any component of the investigational product~* Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.~* Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)~* Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/80 mg (Type: EXPERIMENTAL): The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
- Goserelin (3.6 mg) + bicalutamide (50 mg) (Type: ACTIVE_COMPARATOR): On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).